StoryCompare

COVERAGE GAP

Moderna-Merck Melanoma Vaccine Trial Results

Moderna and Merck's personalized mRNA melanoma vaccine reduced recurrence or death risk by 42% in late-stage trials.

COVERAGE GAPLEFT SOURCES ONLY

WHAT'S CONFIRMED

  • ▸The vaccine reduced cancer recurrence and death risk by 42% compared with standard treatment. — NBC News Health, CNBC

NOT REPORTED ELSEWHERE

  • ▸Six melanoma specialists called the results clinically meaningful for post-surgery melanoma patients. — CNBC

Keep comparing